Table 5.
Percentage of human RBC lysis obtained from the interaction of monothiooxalamides derived from 2-aminopyridine (I) and 2-aminobenzimidazole (II) with human RBCs, compared to the 100 % hemolysis.
| Compound | Hemolysis (%) |
|||
|---|---|---|---|---|
| 500 μg/mL (1.44–2.13 mM) | 100 μg/mL (0.30–0.43 mM) | 50 μg/mL (0.15–0.21 mM) | 25 μg/mL (0.07–0.11 mM) | |
| 1a | 47.59c ± 1.90 | 29.75b ± 1.78 | 10.6b ± 0.43 | 2.96b ± 0.27 |
| 1b | 10.45d ± 0.36 | 2.02c ± 0.61 | 1.03c ± 0.24 | NA |
| 1c | 13.72b ± 0.98 | 2.22c ± 0.12 | 0.72c ± 0.11 | NE |
| 1d | 62.95b ± 1.44 | 28.57b ± 0.44 | 12.97a ± 0.24 | 4.96b ± 0.69 |
| 1e | 70.85a ± 1.13 | 54.40a ± 2.35 | 12.50a ± 0.24 | 1.21b ± 0.27 |
| 1f | 3.31ef ± 0.49 | 1.26c ± 0.12 | 0.75c ± 0.14 | 0.63b ± 0.24 |
| 1g | 3.90e ± 0.27 | 1.66c ± 0.07 | 1.14c ± 0.12 | 0.20b ± 0.12 |
| 1h | 0.59fg ± 0.07 | 0.24c ± 0.38 | NA | NA |
| 2c | 34.50b ± 0.49 | 13.47c ± 0.51 | 12.31b ± 0.29 | 8.24b ± 0.76 |
| 2e | 39.53a ± 1.93 | 23.09a ± 0.34 | 21.25b ± 0.88 | 13.73a ± 0.79 |
| 2g | 20.19c ± 0.78 | 3.26c ± 0.65 | 2.58c ± 0.15 | 2.10c ± 0.20 |
| 2h | 13.85b ± 0.42 | 6.46b ± 0.45 | 4.34b ± 0.52 | 3.05b ± 0.42 |
| I | 0.42g ± 0.30 | 0.07c ± 0.15 | NA | NA |
| II | 1.55d ± 0.10 | 0.71d ± 0.24 | 0.58d ± 0.42# | 0.16d ± 0.11 |
NA: not active. NE: not evaluated. The letters (a-g) in each column refer to the pairwise comparisons between groups with a significant difference according to Tukey's HSD test; n = 3, p < 0.05.